RWE: CAR T-Cell Consortium
Efficacy
PFS/OS
ORR (D90)
41%
CR (D90)
35%
OS AT 12 MONTHS
59%
| Safety | |
|---|---|
| CRSGrade ≥3 | 1% |
| ICANSGrade ≥3 | 1% |
43% of CAR T-Cell Consortium patients would have been ineligible for the JULIET trial
- Reference: 1. Riedell PA et al. Transplant Cell Ther 2022;28(10):669–676.
Data collection
May 2018–May-Dec 2020
(apheresis Jul 2019)
8 US Academic centers
Median follow-up
months
No. of patients infused with tisa-cel
| Median age (range) yearsPatients ≥65 years | 67 (IQR 61–72)62% |
| Gender (male) | 52% |
| ECOG ≥2 | 7% |
| IPI (3-5) | 49% |
| HG lymphoma (double or triple hit) | 7% |
| DLBCL | 85% |
| Transformed lymphoma | 8% |
| Comorbidities | 55% |
| LDH elevated | 42% |
| Prior therapies (median)≥3 lines | 4 (2-9)85% |
| Primary refractoryRefractory to last lineRelapsed | 20%39%40% |
| Prior SCTAuto | 25% |
| Bridging therapy | 74% |
| Median vein to vein time | 45 days |
Limitations: “Tisa-cel recipients were older, more heavily pretreated, had lower comorbidity burden, more commonly had relapsed disease, though less likely to have an elevated LDH”. Old data (apheresis up to July 2019) not reflecting advances in manufacturing and toxicity management
- Reference: 1. Riedell PA et al. Transplant Cell Ther 2022;28(10):669–676.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete